A detailed history of Gsa Capital Partners LLP transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 17,142 shares of FULC stock, worth $77,996. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,142
Previous 135,221 87.32%
Holding current value
$77,996
Previous $838,000 92.72%
% of portfolio
0.0%
Previous 0.06%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$3.18 - $9.74 $375,491 - $1.15 Million
-118,079 Reduced 87.32%
17,142 $61,000
Q2 2024

Aug 15, 2024

BUY
$5.98 - $9.31 $717,952 - $1.12 Million
120,059 Added 791.84%
135,221 $838,000
Q1 2024

May 03, 2024

BUY
$6.7 - $12.0 $101,585 - $181,944
15,162 New
15,162 $143,000
Q3 2022

Nov 14, 2022

SELL
$4.92 - $9.1 $24,319 - $44,981
-4,943 Reduced 21.66%
17,879 $145,000
Q2 2022

Aug 09, 2022

BUY
$4.2 - $24.0 $95,852 - $547,728
22,822 New
22,822 $112,000

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $237M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.